Wednesday, July 8, 2026

Patent intelligence · US

US 11497745

Methods for treating cholestasis

granted A61KA61K31/4995A61K31/554A61K31/7042
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 4
Patent details — US 11497745
Jurisdiction
US
Status
granted
Grant date
Nov 15, 2022
Expiration
Nov 10, 2042
Claims
13
CPC classes
A61K, A61K31/4995, A61K31/554, A61K31/7042
View on Google Patents ↗

Quick answer

US 11497745 (Methods for treating cholestasis) is held by MIRUM PHARMACEUTICALS, INC.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/4995, A61K31/554, A61K31/7042, A61K38/05, A61P

More from MIRUM PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12296050

    Pharmaceutical compositions comprising maralixibat and uses thereof

    MIRUM PHARMACEUTICALS, INC. · Expires May 8, 2045

    granted
  2. US 11918578

    Methods for treating cholestasis

    MIRUM PHARMACEUTICALS, INC. · Expires Feb 29, 2044

    granted
  3. US 11229647

    Methods for treating cholestasis

    MIRUM PHARMACEUTICALS, INC. · Expires Jan 20, 2042

    granted

Frequently asked questions

What is US patent 11497745?

US 11497745 (Methods for treating cholestasis) is held by MIRUM PHARMACEUTICALS, INC.. Status: granted. Granted Nov 15, 2022. Expires Nov 10, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11497745?

MIRUM PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.

When does US 11497745 expire?

Our index shows an expiration date of Nov 10, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.